Forecast the future pattern from 50 drugs with the most drastic price reduction

In the new round of national health insurance negotiations, 70 new varieties were successfully negotiated, with an average decrease of 60.7% The drug use of hepatitis B decreased by more than 85% and tumor diabetes by more than 65% 27 of the 31 renewed drugs were successfully negotiated, down 26.4% Most of the drugs that have been successfully negotiated are newly marketed in recent years and have high clinical value According to experts, in the medical insurance catalog negotiation, several world-famous "noble drugs" were marked with "civilian price", and the imported drugs basically gave the lowest price in the world It is conservatively estimated that through negotiation of price reduction and medical insurance reimbursement, the individual burden of patients will be reduced to less than 20% of the original level, and individual drugs may even be reduced to less than 5% In the above list of 2019top50 price cuts, we first see that: among the drugs with the largest price drop, there are biological drugs, chemical drugs and Chinese patent medicines, and the unit price levels are thousands, hundreds, dozens, pieces and hairs The drug terminal price before the reform and the price lowered by the reform are on two tracks No matter how to expand the scope of volume purchase or medical insurance catalog negotiation, the focus of attracting pharmaceutical enterprises is to expand the market space At the same time, relevant enterprises must actively or passively participate in the pharmacoeconomic evaluation, either exposing the price, the marketing mode and structure, or even the cost A comparison, endless speculation In the decline of medical insurance catalogue negotiation, ginkgolide injection, arginine glutamate and adalimumab decreased 84.87%, 84.75% and 83.5% respectively In the medical insurance catalog negotiation, the price of Qixiong Tongluo capsule was reduced by 81.3%, Tanreqing capsule by 80.45%, salvianolic acid for injection by 80.27%, total glycoside tablets of saffron by 80%, lidocaine by 79.12% In the decline of medical insurance catalogue negotiation, the price of glycyrrhizic acid monoammonium cysteine sodium chloride was reduced by 75.74%, gadolinium glycol by 74.91%, dexamethasone by 73.54%, Duzhi pill by 73.51%, dageling by 73.23%, and tafluprost by 72.3% Carrying quantity purchase is to point out varieties directly Health care negotiations are more focused on the point will, point out drugs From the above quoted price reduction results of health insurance negotiation, although the health insurance negotiation is mainly one-to-one, which is a form of incomplete competition, it is rare and valuable All pharmaceutical companies give up the answer of substantial price compromise, and the overall effect is good For the varieties of Chinese patent medicines that have been greatly compromised in price, if the sales volume can not be realized within the framework of medical insurance payment, it is meaningless for medical insurance, pharmaceutical enterprises and patients If the sales volume is successful, the price of a drug may affect the price of a kind of indication drug, and the price adjustment of this kind of indication drug can widely exaggerate the market price The bargaining machine is the public one in the world, and the innovation of the winner must be matched with it Based on their own production and marketing capabilities, relevant suppliers should pay close attention to the supply at the transaction price level, make every effort to avoid marginalization and shortage, and avoid becoming a key monitoring variety that can only be sold within the framework of medical insurance, but not well sold In the negotiation object of medical insurance, each other's mentality is complex, including the support of new drugs and special drugs, and the suppression of high prices and low prices It's normal for negotiations to fail It is natural for pharmaceutical companies to put forward a passive scenario of volume purchase, which requires pharmaceutical companies to find a way out of technical standards and cost control in the price passivity Three medical linkage gradually weaves three big networks for drug recruitment and acquisition The first is the volume Procurement Based on medical reform, the second is the national negotiation based on medical insurance reform, and the third is the GPO mechanism based on hospital reform Which net is more suitable for innovative medicine, rare disease medicine and Chinese patent medicine? With the normal price regulation, pharmacoeconomic evaluation and low price linkage, the Internet has its own characteristics and commonalities For the drugs listed in the top 50 price reduction list in 2019, when doing pharmacoeconomic evaluation and economic calculation, there is a total budget plate Since the catalog was officially launched on January 1, 2020, it can continue to monitor the implementation of landing on a special, regular and daily basis For medical insurance, price cage can firstly exchange the number of cases and increase the dosage of drugs moderately, then observe the fund space specially saved and think about the effect of exchangeable reform space For pharmaceutical companies, whether they are passive and actively involved in purchasing with quantity or participating in health insurance negotiations with complex mentality, there are always some large-scale attempts on varieties that are losing money Some of the reasons may be that the transaction price is difficult to achieve the expected profit balance, some of the drug companies with reduced prices are difficult to win the favor of the purchasers, and some of the price scissors of drugs normally entering the medical insurance catalog Backtracking from the occurrence data enables the new scheme to develop strengths and avoid weaknesses This round of negotiation allows pharmaceutical companies to choose whether the negotiation price is confidential Finally, a total of 47 drugs (46 western medicine and 1 Traditional Chinese Medicine) have chosen price confidentiality, including three drugs under Novartis In this round of negotiation, only 2 drugs with the lowest cost for the whole course of treatment are allowed to enter the catalogue for 6 hepatitis C drugs, and it is promised that no new drugs of the same kind will be included within 2 years, so the competitive negotiation is effective In the three networks, price is the core of multi game From the perspective of the product itself, the transaction price is the lowest in history, and from the perspective of horizontal comparison, it is lower and lower These goals are subject to our current pharmaceutical payment ability and willingness, as well as the price anchoring problems caused by market comparison and industry shortage Around the price, there are three aspects worth thinking about: